Our weekly scan identified 61 newly registered trials on ClinicalTrials.gov this week, led by rare disease (26) and oncology (21), with additional activity in neurology (5), respiratory (4), endocrinology (3), cardiovascular (1), and immunology (1). Separately, our heuristics flagged 4 enrollment-distress indicators, concentrated in rare disease (3) and infectious disease (1). Our rolling index of the overdue-results backlog also took in new records this week, detailed below.
Several sponsors — including Roche, Janssen, Eurofarma, and Qilu Pharmaceutical — registered Phase 3 programs this week without site counts yet listed, suggesting site activation is still pending.
Our rolling index of the overdue-results backlog — trials completed more than 12 months ago with no results posted — added 208 previously completed trials during this week's scan. Rare disease (106) and oncology (50) made up the bulk of this week's additions, with immunology (11), endocrinology (10), cardiovascular (9), neurology (9), infectious disease (6), and respiratory (7) also represented. This reflects our scan's coverage of a standing backlog that FDA sized at over 3,000 trials in March 2026, not new filings this week.
Four enrollment-distress indicators were newly flagged this week, split between rare disease and infectious disease programs. The small count reflects this week's scan only and should be read alongside cumulative site-level history rather than in isolation.
For operations leaders evaluating new Phase 3 starts this week, site-count disparities are worth watching early: programs launching with zero listed sites warrant a startup-timeline check before committing site-selection resources, particularly in competitive indications like oncology and rare disease.
Eichor generates free preliminary site-risk snapshots from public data for any of the trials referenced above.
---